Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 8786 results

  1. Olezarsen for treating severe hypertrglyceridaemia [TSID12387]

    Awaiting development Reference number: GID-TA12016 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]

    Awaiting development Reference number: GID-TA12017 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Povorcitinib for treating prurigo nodularis [TSID12385]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Povorcitinib for treating non-segmental vitiligo [TSID12388]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]

    Awaiting development Reference number: GID-TA12020 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Upadacitinib for treating moderately to severely active systemic lupus erythematosus [TSID12366]

    Awaiting development Reference number: GID-TA12021 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]

    Awaiting development Reference number: GID-TA11526 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]

    Awaiting development Reference number: GID-TA10967 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    Awaiting development Reference number: GID-TA11624 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date:  13 January 2027

    Technology appraisal guidance
    In development

  11. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Transvaginal radiofrequency Ablation for symptomatic uterine fibroids

    In development Reference number: GID-HTG10538 Expected publication date: TBC

    HealthTech guidance
    In development

  13. Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroids

    In development Reference number: GID-HTG10470 Expected publication date: TBC

    HealthTech guidance
    In development

  14. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015